| Apr 16 |
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
|
| Apr 8 |
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
|
| Mar 26 |
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
|
| Mar 18 |
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
|
| Mar 15 |
Psyence Biomedical gets non-compliance notification from Nasdaq
|
| Mar 15 |
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
|
| Mar 12 |
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
|
| Mar 12 |
Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones
|
| Mar 11 |
Psyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australia
|
| Mar 11 |
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
|
